tenofovir

This page shows the latest tenofovir news and features for those working in and with pharma, biotech and healthcare.

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy

Latest news

GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
Gilead’s Biktarvy gets European approval, setting up battle with GSK

The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).
The year of the blockbuster

Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval

However Gilead has its own direct competitor, Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's Descovy, a combo of emtricitabine and tenofovir alafenamide.
CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There was also good news at the CHMP meeting for Gilead Sciences’HIV division, with the panel giving its blessing to three-drug, fixed-dose therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).

More from news
Approximately 10 fully matching, plus 96 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
Pharma deals during July 2012

Merck has licensed CMX 157 an oral nucleoside reverse transcriptase inhibitor for treatment of HIV that is 200-fold more potent in vitro than tenofovir (Gilead's product with sales of

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Account Director - Digital: Great salary and benefits

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Market Access Consultant - Greater Manchester: Negotiable

Senior Account Manager – Healthcare Advertising: Salary TBC

Senior Medical Writer: Salary is DOE

Systematic Review Lead- London: Negotiable

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Training Manager - Surrey: Competitive Salary &Bonus

Account Manager: Negotiable

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Director or Senior Account Director: Salary TBC

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Healthcare PR Senior Account Manager: Salary TBC

Medical Writer - Creative and Scientific Projects: DOE

Account Director, Healthcare Advertising Agency: Salary TBC

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Editorial Director – Medical Education: Neg

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Graduate Scientific Editor: DOE

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Senior Account Manager / Account Director - Medical Education – ...: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Director – Head of Public Affairs: Neg

Subscribe to our email news alerts

PMHub

Add my company

Aptus Health

Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...

Latest intelligence

Congress Effectiveness Management: Maximising the ROI of scientific meetings...
Biopharma's Future: Made in China: The world’s second biggest pharma market is entering a new growth phase – but meeting its needs takes investment and expertise...
Solaris Health looks at the gene therapy revolution: Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...